ACM
AMRI

Ashford Capital Management’s Albany Molecular Research Inc AMRI Stock Holding History

Ashford Capital Management’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-407,700
Closed -$6.23M – 106
2016
Q1 		$6.23M Buy
407,700
+227,700
+127% +$3.57M 1.48% 23
2015
Q4 		$3.57M Hold
180,000
– – 0.84% 37
2015
Q3 		$3.14M Buy
+180,000
New +$3.66M 0.74% 45

Other funds holding AMRI

PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
OWP
Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Ashford Capital Management's AMRI Position: Q2 2016 in Review

Ashford Capital Management sold out of Albany Molecular Research Inc (AMRI) in Q2 2016, closing a stake of 407,700 shares — an estimated $6.23M sold.

Ashford Capital Management first reported a position in AMRI in Q3 2015 and held it in 3 quarters. The position peaked at $6.23M in Q1 2016. 142 funds tracked by Wall St. Rank hold AMRI as of Q2 2016.

  • Ashford Capital Management reported no remaining Albany Molecular Research Inc position as of Q2 2016 after selling out during the quarter.
  • Ashford Capital Management sold 407,700 Albany Molecular Research Inc shares in Q2 2016, an estimated $6.23M.
  • Ashford Capital Management first reported a position in Albany Molecular Research Inc in Q3 2015 and held it in 3 quarters.
  • Ashford Capital Management's Albany Molecular Research Inc position peaked at $6.23M in Q1 2016.
  • 142 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2016.

Based on Ashford Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.